Calipharms (KGET) Stock Price

Calipharms Price

OTC·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

Calipharms stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Calipharms over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Calipharms stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Calipharms's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Calipharms Stock Price History
DateCalipharms Price
8/4/20260.00 USD
8/3/20260.00 USD
7/30/20260.00 USD
7/29/20260.00 USD
7/28/20260.00 USD
7/27/20260.00 USD
7/24/20260.00 USD
7/23/20260.00 USD
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.00 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/11/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/4/20260.00 USD
5/1/20260.00 USD
4/22/20260.00 USD
4/20/20260.00 USD
4/17/20260.00 USD
4/16/20260.00 USD
4/9/20260.00 USD
4/7/20260.00 USD
3/26/20260.00 USD
3/25/20260.00 USD
3/24/20260.00 USD
3/23/20260.00 USD
3/20/20260.00 USD
3/17/20260.00 USD
3/16/20260.00 USD
3/10/20260.00 USD
3/9/20260.00 USD
3/4/20260.00 USD
3/2/20260.00 USD
2/26/20260.00 USD
2/17/20260.00 USD
2/12/20260.00 USD
2/10/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
1/29/20260.00 USD
1/26/20260.00 USD
1/23/20260.00 USD
1/15/20260.00 USD
1/13/20260.00 USD
1/12/20260.00 USD
1/9/20260.00 USD
1/7/20260.00 USD
1/6/20260.00 USD
1/5/20260.00 USD
12/31/20250.00 USD
12/29/20250.00 USD
12/22/20250.00 USD
12/19/20250.00 USD
12/18/20250.00 USD
12/17/20250.00 USD
12/15/20250.00 USD
12/12/20250.00 USD
12/10/20250.00 USD
12/9/20250.00 USD
12/8/20250.00 USD
12/5/20250.00 USD
12/3/20250.00 USD
12/1/20250.00 USD
11/25/20250.00 USD
11/20/20250.00 USD
11/19/20250.00 USD
11/14/20250.00 USD
11/11/20250.00 USD
11/10/20250.00 USD
11/6/20250.00 USD
11/5/20250.00 USD
11/3/20250.00 USD
10/23/20250.00 USD
10/6/20250.00 USD
9/26/20250.00 USD
9/12/20250.00 USD
9/10/20250.00 USD
9/8/20250.00 USD
8/28/20250.00 USD
8/25/20250.00 USD
8/22/20250.00 USD
8/21/20250.00 USD
8/14/20250.00 USD
8/13/20250.00 USD
8/11/20250.00 USD
Access this data via the Eulerpool API
Get Free API Key

Calipharms Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2012
0.00 USD
-89,400.00 USD
-89,600.00 USD
Jan 1, 2013
0.00 USD
-184,200.00 USD
-213,300.00 USD

Calipharms Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 4:25 PM
 
SHARESB
20122013
2.292.26
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Calipharms generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Calipharms retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Calipharms's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Calipharms has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Calipharms's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Calipharms stock margins

The Calipharms margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Calipharms. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Calipharms.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2012
0.00 %
- %
- %
Jan 1, 2013
0.00 %
- %
- %

Calipharms Stock Revenue, EBIT, Earnings per Share

The Calipharms earnings per share therefore indicates how much revenue Calipharms has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2012
0.00 USD
-0.00 USD
-0.00 USD
Jan 1, 2013
0.00 USD
-0.00 USD
-0.00 USD

Calipharms business model & stock analysis

Calipharms Inc is a global pharmaceutical company specializing in the development, manufacture, and marketing of innovative drugs. The company was founded in 1995 as a small generic drug manufacturer and has since evolved into a state-of-the-art facility that continuously invests in research and development, with the goal of serving patients and healthcare systems worldwide. Calipharms' business model primarily focuses on developing and delivering innovative and differentiated drugs. The company offers a wide range of products divided into various categories, including oncology, immunology, dermatology, gastroenterology, cardiology, and pediatrics. Additionally, Calipharms also produces medications in the fields of neurology, orthopedics, and pain management. One of Calipharms' flagship products is the oncology drug Califox, which is used in the treatment of advanced malignant tumors. It is a human anti-EGFR (HER1) monoclonal antibody that is highly valued for its specific effects and excellent therapeutic efficacy in cancer patients. In addition to the oncology segment, Calipharms also has a strong portfolio of immunology medications. The product Caliplex is an immunosuppressant used in the treatment of autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. This medication inhibits the activity of T lymphocytes, resulting in anti-inflammatory effects and alleviation of pain and stiffness in joints or muscles. Another important product is Caliquin, an analgesic used for the short-term treatment of moderate to severe pain. It is a synthetic opioid that is highly effective in providing pain relief with low toxicity for the patient. In addition to manufacturing innovative drugs, Calipharms also operates a comprehensive research and development department. The company is committed to developing new therapies for some of the world's most neglected diseases, such as tuberculosis, malaria, and HIV/AIDS. Calipharms also collaborates closely with universities and other research institutions to ensure it has the latest knowledge and technologies to continuously improve therapies. In terms of its financial performance, Calipharms has experienced strong growth in recent years. The company has continuously increased its revenue and profit by expanding into new markets and increasing its presence in existing markets. Calipharms has also made several acquisitions in recent years to expand its production capacity and increase its market share. In conclusion, Calipharms is an important global company dedicated to providing innovative drugs and therapies. The company has a wide range of products in various therapeutic areas, from oncology to pain management. With a strong focus on research and development and a robust growth strategy, Calipharms is well-positioned to continue its success in the future.

Calipharms SWOT Analysis

Strengths

Calipharms Inc has a strong reputation in the pharmaceutical industry.

The company has a diverse portfolio of high-quality products.

They have established strategic partnerships with leading healthcare providers.

Calipharms Inc has a highly skilled and experienced management team.

Weaknesses

The company relies heavily on a few key suppliers, which poses a supply chain risk.

Calipharms Inc has limited presence in international markets.

They have struggled to adapt to rapidly changing regulatory environments.

The company lacks significant digital presence and e-commerce capabilities.

Opportunities

The global pharmaceutical market is projected to grow significantly in the coming years, providing opportunities for expansion.

Calipharms Inc can leverage their expertise to develop innovative products and capture market share.

Emerging markets offer untapped potential for growth and diversification.

The increasing demand for personalized medicine opens up new avenues for Calipharms Inc.

Threats

Intense competition in the pharmaceutical industry puts pressure on pricing and profitability.

Stringent regulations and compliance requirements pose risks for Calipharms Inc.

The threat of counterfeit drugs impacts brand reputation and patient safety.

Shifts in healthcare policies and government regulations can impact market dynamics.

Calipharms Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Calipharms historical P/E ratio, EBIT multiple, and P/S ratio

Calipharms annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Calipharms shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2012
2.29 B Stocks
Jan 1, 2013
2.26 B Stocks

Calipharms stock splits

In Calipharms's history, there have been no stock splits.
Price targets and forecasts for Calipharms are not yet available.

Calipharms shareholder structure

% Name
0.00000%
Fisher Investments
Fisher Investments

Calipharms Executives and Management Board

3 members · avg. age 44 · 0 % women

WW

William Wylie (48)

Acting Chief Financial Officer, Director · since 2012

60,000.00 USD

Management

BL

Mr. Bo Linton (39)

President, Chief Executive Officer, Director · since 2014

–

Board of Directors

BG

Bryan Geer

Director

–

Frequently asked questions about Calipharms

The main competitors of Calipharms Inc in the market include major pharmaceutical companies such as Pfizer, Johnson & Johnson, and Merck & Co. These competitors are well-established players in the industry with a strong market presence and a diverse portfolio of products. Calipharms Inc faces intense competition from these companies in terms of research and development, marketing strategies, and overall market share.

The business model of Calipharms Inc focuses on the development and commercialization of pharmaceutical products derived from cannabinoid compounds. The company aims to leverage the potential therapeutic properties of cannabinoids to address various medical conditions. Calipharms Inc conducts research, preclinical and clinical trials, and seeks regulatory approvals for its pharmaceutical products. By utilizing the therapeutic benefits of cannabinoids, Calipharms Inc strives to provide innovative and effective treatments for patients in need.

Calipharms Inc is primarily active in the pharmaceutical and healthcare industries.

Calipharms Inc is a pharmaceutical company headquartered in [location]. With a rich history and a strong background in the industry, Calipharms Inc has been a leading player in the development and commercialization of innovative healthcare solutions. The company has an extensive portfolio of products, ranging from prescription drugs to over-the-counter medications, catering to various therapeutic areas. Armed with state-of-the-art research facilities and a dedicated team of scientists, Calipharms Inc has successfully brought numerous life-saving treatments to market. The company's commitment to delivering high-quality and effective healthcare products has made it a trusted name among consumers and healthcare professionals alike.

Calipharms Inc, a renowned pharmaceutical company, has achieved significant milestones in its journey. With a strong focus on innovation and research, the company has developed groundbreaking drugs and medical solutions that have revolutionized the healthcare industry. Calipharms Inc has successfully obtained multiple patents for its unique drug formulations, enhancing its position as a leading player in the market. Additionally, the company has forged strategic partnerships with renowned healthcare organizations, facilitating global expansion and recognition. Calipharms Inc's commitment to improving patient outcomes and delivering cutting-edge treatments has garnered widespread acclaim, solidifying its reputation as a pioneering force in the pharmaceutical domain.

Calipharms Inc is primarily present in the United States.

Calipharms Inc represents values of innovation, integrity, and excellence in the pharmaceutical industry. With a strong corporate philosophy focused on delivering high-quality healthcare solutions, Calipharms Inc prioritizes patient safety and satisfaction. The company strives to develop and commercialize advanced therapies to address unmet medical needs and improve patient outcomes. Through robust research and development efforts, Calipharms Inc aims to pioneer groundbreaking treatments, driven by a commitment to science and ethical practices. With a relentless pursuit of excellence, Calipharms Inc adopts a customer-centric approach, ensuring the highest standards of quality and efficacy in all its pharmaceutical products.

Converted at the current exchange rate, the Calipharms share trades at 0.00 EUR (0.00 USD).

Calipharms Inc is a Las Vegas based company specializing in the production and marketing of medical cannabis products. The company's business model focuses on five core areas: production, research, development, marketing, and distribution.

The revenue cannot currently be calculated for Calipharms.

The profit cannot currently be calculated for Calipharms.

The P/E ratio cannot be calculated for Calipharms at the moment.

The P/S cannot be calculated for Calipharms currently.

The Eulerpool Quality Score for Calipharms is 2/10.

The ISIN of Calipharms is US4984561021. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Calipharms is A1JFVQ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Calipharms is KGET. The ticker symbol is used to trade Calipharms shares on the stock exchange.

Calipharms paid dividends every year for the past 0 years.

Calipharms is assigned to the 'Industry' sector.

The dividends of Calipharms are distributed in USD.

All fundamentals and in-depth analysis of Calipharms

Our stock analysis for Calipharms stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Calipharms. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Calipharms Stock
Calipharms Revenue→
Calipharms Stock
Calipharms Net Income→
Calipharms Stock
Calipharms P/E→
Calipharms Stock
Calipharms P/S→
Calipharms Stock
Calipharms EBIT→
Calipharms Stock
Calipharms Dividend→
Calipharms Stock
Calipharms Directors Dealings→
Calipharms Stock
Calipharms Stocks→
Calipharms Stock
Calipharms Market capitalization→
Calipharms Stock
Calipharms Debt→
Calipharms Stock
Calipharms Liabilities→
Calipharms Stock
Calipharms Equity→
Calipharms Stock
Calipharms AAQS→
Calipharms Stock
Calipharms Employees→
Calipharms Stock
Calipharms ROE→
Calipharms Stock
Calipharms ROA→
Calipharms Stock
Calipharms ROCE→
Calipharms Stock
Calipharms News→
Calipharms Stock
Calipharms Analyst Price Targets→

Industry Stocks

Callan JMBCalian GroupCalvert InternationalCaldwell Partners InternationalCalviks AB (publ)Cakra Buana Resources Energi PT TbkCamber EnergyCahayasakti Investindo Sukses Tbk PTCambi ACahayaputra Asa Keramik Tbk PTCamel Group CoCahaya Aero Services Tbk PTAll Stocks A–Z →